New drug expenditure is 13.5% of NHI finance's drug spending
By Whang, byung-woo | translator Hong, Ji Yeon
24.10.23 05:01:37
가나다라
0
KRPIA has presented research outcome of 'Analysis of pharmaceutical spending on new drugs by disease'
New drug expenditure in the highest costing disease category is relatively lower than the international average
Emphasizes the need to improve the pharmaceutical cost expenditure system and reimbursement for severe disease treatments
It was found that the total expenditure on new drugs listed in the past six years since the Positive List System policy was implemented amounted to 13.5% of the National Health Insurance pharmaceutical spending, which is the lowest compared to the averages of A8 countries and OECD countries.
The research evaluated new drugs listed from 2007 to 2022 when the Positive List System policy was implemented to allocate fina
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)